| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |